JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials. This is an ASCO Meeting ...

Investigators evaluated atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for patients with recurrent ovarian cancer.

Researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack -- blocking the energy supply T cells depend on. The work points toward a promising new ...

Scientists at the Icahn School of Medicine at Mount Sinai have discovered a way ovarian cancer (OvCa) tumors can manipulate their environment to resist immunotherapy. The team’s research, involving ...

Ovarian cancer remains one of the most difficult-to-treat diseases. With all our advances in screening and molecular profiling, it still maintains the worst death-to-diagnosis rate among gynecologic ...

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. The study, ...

Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial ...

Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders, ...

Eterna Therapeutics announced promising preclinical results for its lead cell therapy, ERNA-101, aimed at treating ovarian cancer by activating the immune system. In a study conducted at MD Anderson, ...

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. The work, published ...